Indefinite Delivery Contract 75N93022D00015
Award Date
1/14/22
Last Date to Order
1/13/32
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Pricing Type
Cost Plus Fixed Fee
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the Department of Health and Human Services (HHS), to Allucent Government Services (Us) LLC, a for-profit clinical research organization. The $550 million single-award IDC provides clinical trial planning and execution services in support of ASPR's medical countermeasure programs, including for chemical, biological, radiological, nuclear,...
This is a multiple award Indefinite Delivery Contract (IDC) awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to provide comprehensive early phase clinical trial services. The $346.6 million contract, titled "Early Phase Clinical Trial Units (EPCTU)", facilitates Phase 0 through Phase II trials of investigational products against infectious diseases over a 10-year ordering period from...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded an indefinite-delivery/indefinite-quantity (IDIQ) contract to Duke University's Office of Research Administration Division to support Phase 0 through Phase II clinical trials of investigational products against infectious diseases. The IDIQ contract, valued at up to $346,610,277, has a performance period from January 14, 2022 to January 13, 2032. Under this IDIQ, Duke...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract titled "Early Phase Clinical Trial Units (EPCTU)" to Icon Government And Public Health Solutions, Inc., a foreign-owned, for-profit organization. The $346.6 million IDIQ will support Phase 0 through Phase II clinical trials of investigational products against infectious diseases over a 10-year...
The National Institute of Allergy and Infectious Diseases awarded an indefinite delivery contract to FHI Clinical Inc. to provide comprehensive and rapid response research programs. The contract has a potential value of $545,452,906 over a seven-year ordering period through August 2028. Two task orders have been issued against it to date, one for $332,178 and another for $2,000. Under the contract, FHI Clinical Inc. will support the NIAID's mission to conduct biomedical research on infectious,...
This Indefinite Delivery Contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Dynport Vaccine Company LLC, a subsidiary of General Dynamics. The contract, valued at a ceiling of $346,610,277, is for Early Phase Clinical Trial Units (EPCTU) services to support Phase 0 through Phase II clinical trials of investigational products targeting infectious diseases. The contract has a period of performance through...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to PPD Development LP with a potential value of $545,452,906 to provide comprehensive and rapid response capabilities for research programs through September 2028. Task orders issued against the contract include over $132 million for clinical trial management support services relating to COVID-19, as well as orders valued at $2.33 million, $2 million, and $82.5...
The National Institute of Allergy and Infectious Diseases awarded an indefinite delivery contract to The Emmes Company LLC on September 1, 2021. With a potential value of $545,452,906 over seven years, this single award IDC supports NIAID's research programs through a broad range of services. Task Order 1 issued under the contract is a firm fixed price order valued at $2,000 to satisfy minimum requirements. Performance will take place in Potomac, MD from September 1, 2021 through August 31,...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract worth up to $107,274,471 to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B and C, and tuberculosis. This multiple-award IDIQ contract has a 7-year period of performance from October 2020 to October 2027. The scope...
The National Institute of Allergy and Infectious Diseases has awarded an indefinite delivery contract with a potential value of $107,274,471 to multiple prime contractors to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Task orders will be issued under seven task areas, including in vitro testing, synthesis of therapeutic agents, small animal...